We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Aldeyra Therapeutics Inc
9 own
14 watching
Current Price
$6.18
$-0.02
(-0.32%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
361.9M
52-Week High
7.99
52-Week Low
2.355
Average Volume
0.27M
Dividend Yield
--
P/E Ratio
--
Market Capitalization361.9M52-Week High7.9952-Week Low2.355Average Volume0.27MDividend Yield--P/E Ratio--What does the Aldeyra Therapeutics Inc do?
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company s lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Read More
How much money does Aldeyra Therapeutics Inc make?
News & Events about Aldeyra Therapeutics Inc.
Business Wire
1month ago
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADX2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma, a rare...
Business Wire
1month ago
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced demonstration of target engagement and improvement in the signs of alcohol intoxication in a sequence-randomized, double-masked, placebo-controlled crossover Phase 2 clinical trial of ADX-629, a first-in-class orally administered...
Business Wire
2 months ago
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. The NDA...
Business Wire
3 months ago
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that an oral presentation highlighting clinical data from the Phase 3 INVIGORATE allergen chamber trial of reproxalap in allergic conjunctivitis will be presented at the American Academy of Optometry 2022 Annual Meeting, taking...
Business Wire
6 months ago
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended June 30, 2022. The second half of 2022 is...
Frequently Asked Questions
Frequently Asked Questions
What is Aldeyra Therapeutics Inc share price today?
Can Indians buy Aldeyra Therapeutics Inc shares?
How can I buy Aldeyra Therapeutics Inc shares from India?
Can Fractional shares of Aldeyra Therapeutics Inc be purchased?
What are the documents required to start investing in Aldeyra Therapeutics Inc stocks?
What is today’s traded volume of Aldeyra Therapeutics Inc?
What is today’s market capitalisation of Aldeyra Therapeutics Inc?
What is the 52-Week High and Low Range of Aldeyra Therapeutics Inc?
What percentage is Aldeyra Therapeutics Inc down from its 52-Week High?
What percentage is Aldeyra Therapeutics Inc up from its 52-Week Low?
Current Price
$6.18
$-0.02
(-0.32%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.